Five (non-cancer) areas Bristol-Myers Squibb is pursuing hard
VP Donnie McGrath said at this week's RESI conference in Houston that Bristol-Myers Squibb is targeting heart failure, virology, immunoscience, rare disease and fibrosis.
Videos at discharge emphasize showing rather than telling heart failure patients how to change behavior
When congestive heart failure patients leave hospitals, a healthcare media startup wants them to be given a parting gift at discharge: a DVD. The idea is to help patients better understand their care plan by showing them what they need to do to change their behavior and avoid becoming a rapid readmission statistic and to […]
presented by
Transforming Patient Care: The Role of AI-Powered Assistants
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Up to 8% of people from South Asian countries carry a mutated gene that can cause heart failure
A new study is looking at a gene mutation (MYBPC3), which affects up to 8 percent of people from India, Pakistan, Bangladesh and other South Asian countries, with the hope of developing new treatment or prevention strategies. An estimated 55 million people of South Asian descent worldwide, including 200,000 people in the United States, carry […]
Heart failure startup CardioKinetix gets $50M in round led by Edwards Lifesciences
Heart failure device startup CardioKinetix should have ample funding to wrap up a pivotal clinical trial that’ll allow it to receive pre-market approval from the FDA: It just raised $50 million in financing, led by Edwards Lifesciences Corp. – which also scooped up exclusive rights to acquire CardioKinetix based on future regulatory milestones. Menlo Park-based CardioKinetix has […]
Novartis’ next blockbuster? New drug cuts heart failure death rate a stunning 20 percent
Novartis could be on the verge of its next blockbuster. The Swiss pharma giant’s new heart failure drug could prove to replace the current standard of therapy, the company announced Saturday. A wide-spanning heart failure study found that Novartis’ drug candidate LCZ696 cut cardiovascular deaths by 20 percent when compared to ACE-inhibitors, which have been the go-to heart failure treatment […]
C-Pulse device designed to help patients with advanced heart failure
A company that has created a unique new therapy for patients with advanced heart failure is hoping to spread the word about its product in 2014, after a year of clinical trials in both Europe and the United States. Sunshine Heart, based in Eden Prairie, MN, raised more than $61 million in 2013, after two […]
presented by
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
SynCardia raises another big round to build a new version of artificial heart
An artificial heart maker in Tucson, Ariz., has raised $14 million to go small with its temporary Total Artificial Heart. Syncardia wants to build a 50cc version of the device. SWK Holdings Corporation contributed $10 million to this round. SWK is a publicly traded, specialized finance company with a focus on the global healthcare sector. […]
Hospital leaders’ 6 top strategies for preventing 30-day readmissions with coordinated care
Eighty-five percent of healthcare executives in a new survey said their organization’s business plan addresses the CMS penalty for 30-day readmissions, and there are a few particular strategies many of them seem to be using. HealthLeaders Media asked 106 health system CEOs and physicians at 75 hospitals how their organizations are dealing with the reimbursement […]
Minnesota company raises $29.6 million for implantable hypertension technology
CVRx, a Minneapolis-based firm that has developed proprietary implantable technology for the treatment of high blood pressure and heart failure, has raised $29.6 million for advancing clinical trials of its Barostim Neo, as well as expanding commercial activities abroad. Johnson & Johnson Development Corp. and New Enterprise Associates, Inc. were the co-lead investors. According to […]